JP2010132668A5 - - Google Patents

Download PDF

Info

Publication number
JP2010132668A5
JP2010132668A5 JP2010000907A JP2010000907A JP2010132668A5 JP 2010132668 A5 JP2010132668 A5 JP 2010132668A5 JP 2010000907 A JP2010000907 A JP 2010000907A JP 2010000907 A JP2010000907 A JP 2010000907A JP 2010132668 A5 JP2010132668 A5 JP 2010132668A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
treatment
composition according
montelukast sodium
hemisorbate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010000907A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010132668A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2010132668A publication Critical patent/JP2010132668A/ja
Publication of JP2010132668A5 publication Critical patent/JP2010132668A5/ja
Withdrawn legal-status Critical Current

Links

JP2010000907A 2003-04-15 2010-01-06 モンテルカストナトリウムの多形形態 Withdrawn JP2010132668A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46294103P 2003-04-15 2003-04-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006509926A Division JP2006523699A (ja) 2003-04-15 2004-04-12 モンテルカストナトリウムの多形形態

Publications (2)

Publication Number Publication Date
JP2010132668A JP2010132668A (ja) 2010-06-17
JP2010132668A5 true JP2010132668A5 (enExample) 2011-03-17

Family

ID=33300016

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006509926A Pending JP2006523699A (ja) 2003-04-15 2004-04-12 モンテルカストナトリウムの多形形態
JP2010000907A Withdrawn JP2010132668A (ja) 2003-04-15 2010-01-06 モンテルカストナトリウムの多形形態

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006509926A Pending JP2006523699A (ja) 2003-04-15 2004-04-12 モンテルカストナトリウムの多形形態

Country Status (7)

Country Link
US (1) US7560559B2 (enExample)
EP (1) EP1633357A4 (enExample)
JP (2) JP2006523699A (enExample)
CN (1) CN1852713B (enExample)
AU (1) AU2004229507B2 (enExample)
CA (1) CA2522053C (enExample)
WO (1) WO2004091618A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1709002A2 (en) * 2004-01-30 2006-10-11 Teva Pharmaceutical Industries Ltd. Montelukast sodium polymorphs
KR20060117356A (ko) * 2004-01-30 2006-11-16 테바 파마슈티컬 인더스트리즈 리미티드 몬테루카스트 유리산 다형체
CA2563776A1 (en) 2004-04-21 2005-11-10 Teva Pharmaceutical Industries Ltd. Processes for preparing montelukast sodium
US20080146809A1 (en) * 2004-11-19 2008-06-19 Matrix Laboratories Ltd Process for the Preparation of Novel Amorphous Montelukast Sodium
KR20090015186A (ko) 2005-07-05 2009-02-11 테바 파마슈티컬 인더스트리즈 리미티드 몬테루카스트의 정제
US8178680B2 (en) * 2005-12-13 2012-05-15 Msn Laboratories Limited Process for the preparation of Montelukast and its pharmaceutically acceptable salts
US8115004B2 (en) * 2006-11-20 2012-02-14 Msn Laboratories Limited Process for pure montelukast sodium through pure intermediates as well as amine salts
WO2010064257A1 (en) * 2008-12-01 2010-06-10 Innogent Laboratories Private Limited Novel intermediates for producing [r-(e)]-1-[[[1-[3-[2-(7- chloro -quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy- methylethyl) phenyl]propyl]thio] methyl] cyclopropaneacetic acid, monosodium salt and process thereof
EP2287154A1 (en) 2009-07-14 2011-02-23 KRKA, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast
WO2011033470A1 (en) 2009-09-16 2011-03-24 Ranbaxy Laboratories Limited Crystalline form of montelukast sodium
US20110195042A1 (en) * 2010-02-10 2011-08-11 Thomas Edward Huetter Compositions, Methods and Kits Useful for Treating a Respiratory Symptom
EP2552892A1 (en) 2010-03-31 2013-02-06 KRKA, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast and novel crystalline form of intermediates therein
KR100990046B1 (ko) 2010-07-30 2010-10-26 동국제약 주식회사 신규한 몬테루카스트 4-할로 벤질아민염 및 이를 이용한 몬테루카스트 나트륨염의 제조방법
US8471030B2 (en) 2010-12-06 2013-06-25 Orochem Technologies Inc. Purification of montelukast using simulated moving bed
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
CN104055741B (zh) * 2013-03-18 2017-02-15 青岛大学 一种孟鲁司特钠片剂及其制备方法
CN104649968B (zh) * 2013-11-25 2017-03-15 天津汉瑞药业有限公司 一种孟鲁司特钠倍半水合物化合物
JP2017503814A (ja) 2014-01-22 2017-02-02 タケダ ゲー・エム・ベー・ハーTakeda GmbH 部分的コントロール状態の重症喘息またはコントロール不良状態の重症喘息のpde4インヒビターを用いた(およびロイコトリエン調節薬と組み合わせて用いた)治療
CN107049940A (zh) * 2017-03-10 2017-08-18 重庆西南医院 一种促进孟鲁司特钠经直肠吸收的促进剂及其使用方法
CN107162969A (zh) * 2017-07-05 2017-09-15 成都亿知科技有限公司 孟鲁司特钠晶体及其制备方法和药物组合物
US10966943B2 (en) 2018-09-06 2021-04-06 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565473A (en) * 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
TW448160B (en) * 1993-12-28 2001-08-01 Merck & Co Inc Novel dicyclohexylamine salt and process for the preparation of leukotriene antagonists
US5523477A (en) * 1995-01-23 1996-06-04 Merck & Co., Inc. Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid
US5869673A (en) * 1997-02-28 1999-02-09 Merck & Co., Inc. Process for 3-(2-(7-chloro-2-quinolinyl)ethenyl) - benzaldehyde
US5952347A (en) * 1997-03-13 1999-09-14 Merck & Co., Inc. Quinoline leukotriene antagonists
AU6391199A (en) * 1998-10-09 2000-05-01 Schering Corporation Composition and method for treating allergic diseases
WO2002067938A2 (en) * 2000-10-30 2002-09-06 Schering Corporation Treating or reducing the risk of cardiovascular disease
WO2003066598A1 (en) * 2002-02-07 2003-08-14 Dr. Reddy's Laboratories Ltd. Novel anhydrous amorphous forms of montelukast sodium salt

Similar Documents

Publication Publication Date Title
JP2010132668A5 (enExample)
JP2013509429A5 (enExample)
JP2018024682A5 (enExample)
JP2014507446A5 (enExample)
JP2012107057A5 (enExample)
JP2013014622A5 (enExample)
JP2013525444A5 (enExample)
JP2014500861A5 (enExample)
JP2013032389A5 (enExample)
JP2009545527A5 (enExample)
JP2011105738A5 (enExample)
IL226853A (en) Annotations of 3 [(2,1-oxazole-4-yl) methoxy] -8-azabicyclo [1.2.3] octane, processes for their preparation, pharmaceutical preparations containing them and their use in the preparation of drugs for the treatment of fxr
JP2011006431A5 (enExample)
MX2011008799A (es) Polipeptidos, dominios variables de anticuerpos, y antagonistas anti-tnfr1 mejorados.
JP2014503593A5 (enExample)
JP2014524442A5 (enExample)
JP2012512907A5 (enExample)
JP2011527299A5 (enExample)
JP2012503668A5 (enExample)
JP2014507477A5 (enExample)
WO2006117300A3 (en) Crystalline forms of tiotropium bromide
TW200708513A (en) Novel crystalline forms of tiotropium bromide
MY159172A (en) Inhalable particles comprising tiotropium
JP2008513510A5 (enExample)
JP2015522037A5 (enExample)